Antidrug antibodies in psoriasis: a systematic review
- 18 February 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 170 (2), 261-273
- https://doi.org/10.1111/bjd.12654
Abstract
Antidrug antibodies (ADAs) against biological agents may be clinically significant and potentially alter a biological drug's treatment efficacy. This systematic review aims to (i) determine the prevalence of ADAs against infliximab, etanercept, adalimumab and ustekinumab in patients with psoriasis; (ii) ascertain whether ADAs are associated with changes in drug efficacy; and (iii) explore the use of concomitant methotrexate to prevent ADA formation. Through a systematic search using Medline and Embase from 29 January 1950 to 29 March 2013, we identified 25 studies that met the inclusion criteria. Of 7969 patients with psoriasis, 950 tested positive for ADAs. Antibodies against infliximab, etanercept, adalimumab and ustekinumab were reported in 5·4-43·6%, 0-18·3%, 6-45% and 3·8-6% of patients, respectively. Anti-infliximab antibodies were associated with lower serum infliximab concentrations in three studies, and decreased treatment response in five studies. ADAs against etanercept were non-neutralizing and not associated with any apparent effects on clinical response. Antiadalimumab antibodies were associated with lower serum adalimumab concentrations in three of five studies, and reduced clinical efficacy in four studies. Two of six studies reported that antiustekinumab antibodies were associated with lower Psoriasis Area and Severity Index responses, and three ustekinumab studies noted that most of these antibodies were neutralizing. Although the use of concomitant methotrexate with biological agents to prevent ADA formation in other immune-mediated diseases is promising, their use in psoriasis is sparse. ADA development remains a challenge with biological therapies and therefore should be considered in patients with psoriasis who experience diminished treatment response.Keywords
This publication has 59 references indexed in Scilit:
- Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 studyJournal of the European Academy of Dermatology and Venereology, 2012
- Coronary Artery Disease in Patients With Psoriasis Referred for Coronary AngiographyThe American Journal of Cardiology, 2012
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004Journal of the American Academy of Dermatology, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007
- Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis VulgarisThe Journal of Experimental Medicine, 2004
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesionsClinical and Experimental Immunology, 1994
- Clinical Safety, Tolerability, and Pharmacokinetics of Murine Monoclonal Antibody to Human Tumor Necrosis Factor-The Journal of Infectious Diseases, 1994
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proceedings of the National Academy of Sciences, 1989
- Production of functional chimaeric mouse/human antibodyNature, 1984